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This paper reports the results of an empirical study of
the Australian medical biotechnology industry, involv-
ing surveys and interviews with participants in research
institutions, companies and diagnostic facilities.
Despite ongoing concerns about the impact of gene and
research tool patents on downstream research and
development, this study reveals evidence of liberal
licensing practices associated with some essential or
foundational inventions within the Australian industry.
However, there are also significant challenges, including
negotiating difficulties, restrictive licence terms, refus-
als to license and stacking royalties. Hence some con-
sideration of the options for law reform is warranted.
Introduction
There is ongoing debate both within Australia and
internationally about the ways in which patents impact
on the medical biotechnology industry. The underlying
purpose of the patent system is to encourage innovation
by granting the patent holder a temporary monopoly
over the patented invention. However, patents can also
have a detrimental effect on innovation, for example, by
stifling the free flow of information or increasing trans-
action costs.1 Gene patents and broadly applicable
research tool patents are of particular concern for two
main reasons. First, if individual patents are licensed on
a restrictive basis, access to broadly applicable founda-
tional technology could be blocked, impeding down-
stream research and development. Secondly, if it is
necessary to enter into licence negotiations over multi-
ple patents, the pace of innovation could be delayed,
creating what has become known as an anticommons.
Despite the large body of theoretical literature on this
topic, the empirical literature is only small (but grow-
ing). To date, empirical literature from the United
States and Europe suggests that practical means are
being found to work around the negative aspects of
patenting in the medical biotechnology industry.2 In
particular, broadly applicable research tools tend to be
widely licensed. However, there is some evidence that
gene patents are having a negative impact in the diag-
nostics sector of the industry in the United States.3
Governments in countries like Australia are actively
promoting the development of indigenous biotechnol-
ogy industries and are putting in place structures to
assist in this goal.4 However, there has been little or no
analysis of the impact of patents and technology transfer
on the commercial success of the Australian biotechnol-
ogy industry, on the capacity of Australian research
institutions to continue with their world-class research
and on consumer access to the products of biotechnol-
ogy research, particularly health care products. The
challenge is whether the current legal and administra-
tive arrangements are satisfactory and, if not, the extent
to which they will need to be reformed. This article
reports the results of a study that was undertaken in
order to provide empirical data to assist in addressing
this challenge.5 This study was referred to extensively
1 A vast body of academic literature exists on this issue, which
is impossible to list fully here. See particularly: M. Heller and R.
Eisenberg, ‘‘Can Patents Deter Innovation? The Anticommons
in Biomedical Research’’ (1998) 280 Science 698; R. S. Eisen-
berg, ‘‘Bargaining over the Transfer of Proprietary Research
Tools: Is this Market Failing or Emerging?’’ in Expanding the
Boundaries of Intellectual Property: Innovation Policy for the Knowl-
edge Society (R. C. Dreyfuss, D. L. Zimmerman and H. First ed.,
Oxford University Press, 2001), pp.228–229; C. Long, ‘‘Propri-
etary Rights and why Initial Allocations Matter’’ (2000) 49
Emory Law Journal 823. Similarly, a large number of reports and
other policy documents consider the potentially detrimental
effect of patents in medical biotechnology. Important recent
reports include the Nuffield Council on Bioethics, The Ethics of
Patenting DNA: A Discussion Paper (Nuffield Council, London,
2002); National Research Council (NRC), Intellectual Property
Rights and Research Tools in Molecular Biology (National Academy
of Sciences, Washington D.C., 1997); Australian Law Reform
Commission, Report 99, Genes and Ingenuity: Gene Patenting and
Human Health (Commonwealth of Australia, Canberra, 2004),
also available at:www.austlii.edu.au/au/other/alrc/publications/
reports/99/ (last accessed May 18, 2005) (‘‘ALRC Report’’).
2 Leading studies in the area include: J. Walsh, A. Arora and W.
Cohen, ‘‘Effects of Research Tool Patenting and Licensing on
Biomedical Innovation’’ in Patents in the Knowledge-Based Econ-
omy (W. M. Cohen and S. A. Merrill ed., National Academies
Press, Washington, 2003), p.287, available at http://books.nap.
edu/books/0309086361/html/285.html#pagetop (last accessed May
18, 2005) (also see Walsh et al., ‘‘Working through the Patent
Problem’ (2003) 299 Science 1021); and J. Straus, H. Holzapfel
and M. Lindenmeir, Empirical Survey on Genetic Invention and
Patent Law (Munich, 2002) (copy on file with the authors). For
a summary of the key issues see OECD, Genetic Inventions, Intel-
lectual Property Rights and Licensing Practices: Evidence and Policies
(OECD, Berlin, 2002), available at www.oecd.org/dataoecd/
42/21/2491084.pdf (last accessed May 18, 2005) and for a
shorter summary see OECD, Patents and Innovation: Trends and
Policy Changes (OECD, 2004), p.22, available on the OECD
website at www.oecd.org (accessed May 18, 2005).
3 J. F. Merz, D. G. Kriss, D. D. G. Leonard and M. K. Cho,
‘‘Diagnostic Testing Fails the Test’’ (2002) 415 Nature 577; M.
K. Cho, S. Illangasekare, M. A. Weaver, D. G. B. Leonard and
J. F. Merz, ‘‘Effect of Patents and Licenses on the Provision of
Clinical Genetic Testing Services’’ (2003) 5 Journal of Molecular
Diagnostics 3.
4 See, for example, Biotechnology Australia, Australian Bio-
technology: A National Strategy (Commonwealth of Australia,
Canberra, 2000), p.7, available at www.biotechnology.gov.au/
library/content_library/BA_Biotech_strategy.pdf (last accessed May
18, 2005).
5 Detailed results of this study are provided in a comprehen-
sive report: D. Nicol and J. Nielsen, ‘‘Patents and Medical Bio-
technology: An Empirical Analysis of Issues Facing the
Australian Industry’’, Centre for Law and Genetics Occasional
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by the Australian Law Reform Commission in its
inquiry into gene patenting and human health in Aus-
tralia.6 The inquiry considered and made recommenda-
tions on a range of important issues associated with
patenting and licensing practices.
Study methodology
There were two components to this study. First, written
surveys were mailed to three industry sectors:
(1) The research sector, including universities, gov-
ernment research laboratories, public and private
research institutes and hospitals, collectively
referred to as research institutions hereafter.
Printed surveys were mailed out to 39 research
institutions in March 2003 and reminder letters
were sent in June 2003. Institutions were identified
by prior knowledge of the research sector and using
standard search engines. The survey asked 42 ques-
tions about research activities, the institution’s
involvement in patenting, collaborations and licens-
ing, awareness of patents held by others and views
on patenting. Twenty-three surveys were returned,
yielding a response rate of 59 per cent.
(2) Biotechnology and pharmaceutical companies
across the full spectrum, from upstream spin offs
from research institutions through to downstream
subsidiaries of multinational pharmaceutical com-
panies. Approximately 180 surveys were mailed to
companies in June 2002.7 The same survey was
sent to both biotechnology and pharmaceutical
companies. Follow-up letters were sent to respon-
dents four weeks after the surveys were mailed out,
and follow-up telephone calls were subsequently
made. The survey asked 52 questions about the
structure and activities of the company, the com-
pany’s involvement in patenting, collaborations and
licensing, and the views of the respondent on pat-
enting within the industry. Forty-nine completed
surveys were returned, yielding a response rate of
27 per cent.
(3) Diagnostic facilities offering clinical genetic
testing and, in some instances, undertaking diag-
nostic research. Printed surveys were mailed out to
the laboratories offering diagnosis of genetic dis-
orders listed on the Human Genetic Society of Aus-
tralasia’s website8 in November 2002 and reminder
letters were sent in December 2002. The surveys
asked 61 questions about the laboratory and its
clinical activity, research and patent activity and
collaborations. A total of 52 surveys were dis-
patched. Eighteen completed surveys were
returned (35 per cent response rate). These
detailed surveys were supplemented by short tele-
phone surveys conducted in March and April 2003
asking six questions about the laboratory, the tests
it performs, payment of licence fees and/or royal-
ties, receipt of notifications from patent or licence
holders, responses to notifications, and views on
patents. These questions were only asked if respon-
dents indicated that they had not returned the writ-
ten survey. Hence telephone survey respondents
did not overlap with the written survey respon-
dents. There were 13 responses to the telephone
survey, yielding a total response rate of 60 per cent
for these questions.9
The second component of the study involved semi-
structured interviews with participants in all of these
sectors. Between August 2002 and July 2003, 40 inter-
views were conducted with respondents from private
companies, research institutions and diagnostic testing
facilities, as well as other industry and government per-
sonnel. Participants were selected based on prior con-
tacts, media reports, internet-based search engines and
databases, and snowball sampling. They were asked a
series of questions that conformed to a flexible format.
The duration of the interviews was generally between
45 minutes and one hour.
Respondents were selected to provide a representa-
tive sample of various sectors within the Australian
industry, from research institutions and companies
operating at the upstream end of the industry, through
to companies involved in downstream drug develop-
ment and therapeutic applications. Within the category
of private sector companies, chief operating executives,
intellectual property personnel and bench scientists
were interviewed. Research institution interviewees
included directors of research groups, bench scientists
and technology transfer personnel. Within the category
of diagnostic testing facilities, directors of research
groups were interviewed. A number of other respon-
dents with expertise in the area were also interviewed,
including patent attorneys, licensing consultants and
government and trade representatives. Interviews were
conducted on a confidential basis because of the nature
of the data being gathered; non-disclosure of identifying
information is standard practice in studies of this nature
and a pilot investigation indicated that people would be
reluctant to participate without an assurance of confi-
dentiality.
Some key areas of inquiry in both surveys and inter-
views were as follows:
u the nature of the research that is being under-
taken by the Australian medical biotechnology
industry and the patent activity associated with it;
u whether the Australian industry has the capacity
to commercialise its own technology, or has to
transfer this technology for others to commercia-
lise;
Paper No.6 (2003), available at www.ipria.org/publications/
reports.html (last accessed May 18, 2005) (‘‘Nicol and Nielsen
Report’’).
6 See ALRC Report, n.1 above.
7 In 2001 Ernst & Young estimated the number of core bio-
technology companies in Australia at 190: Ernst & Young, Aus-
tralian Biotechnology Report (Commonwealth of Australia, 2001).
In this study, surveys were sent to those companies for whom
contact details could be found using standard search techniques.
It should be noted that the number of biotechnology companies
in Australia has risen significantly since the 2001 Ernst and
Young Report. See ALRC Report, n.1 above, at pp.401–409.
8 At www.hgsa.com.au/ (last accessed May 18, 2005).
9 Results of this aspect of the study are reported in D. Nicol,
‘‘The Impact of Patents on the Delivery of Genetic Tests in
Australia’’ (2003) 15/5 Today’s Life Science 22 as well as the Nicol
and Nielsen Report, n.5 above, at pp.196–207.
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u the extent of collaborations, assignments and
licensing-out of patents held by the Australian
industry and the nature of the arrangements;
u the general terms and conditions contained in
licences entered into by the Australian industry for
the purposes of commercialising research (licens-
ing-out);
u the extent to which the Australian industry needs
to obtain authorisation from other patent holders in
order to carry out its research and commercialisa-
tion, specifically focusing on the types of patents
that are being enforced in Australia and the quan-
tum of in-licensing;
u the general terms and conditions contained in
licences entered into by the Australian industry for
the purposes of obtaining access to patents held by
others; and
u ·the particular issues faced by the research
institution, diagnostics and private industry sec-
tors.
Study findings
A key finding of this study is that a very delicate balance
exists between the role played by patents in encouraging
innovation and the potential for patents to impact neg-
atively on research into, and the development of, new
drugs, devices, therapies and diagnostics. While the
existing system is not perfect, great care will need to be
taken in modifying this system to ensure that the bal-
ance is not too greatly disturbed. The primary conclu-
sion from this study is that while there is some scope for
legal intervention, given that a fairly vibrant medical
biotechnology industry is developing and operating in
Australia, any reform should be at the margins. To jus-
tify this finding, key outcomes are briefly outlined
below.
Research and patent issues
There are concerns in all sectors of the industry about
the breadth of some of the patents that were granted in
the 1990s. However, respondents generally acknowl-
edged that issues surrounding broad patents are being
resolved in some jurisdictions. In particular, the US
Patents and Trademarks Office has narrowed the scope
of acceptable claims and US courts are striking down
overly broad claims. There was some criticism of the
Australian Patent Office by respondents in this study. In
particular, it was felt that the Patent Office allows overly
broad claims to be granted. The lack of Australian bio-
technology case law exacerbates this problem because
the Patent Office is not being given any guidance by the
courts as to biotechnology claims interpretation. Thus,
while some concerns were raised by respondents about
the quality of patents being granted in Australia, the
issues raised seem to be related more to resources and
the application of existing patent law standards rather
than the constitution of those standards.
There are ongoing concerns about the impact of gene
patents on downstream research. There are also some
concerns about research tool patents, although in gen-
eral they would seem to be less an issue in Australia than
in the United States. In part the reason for this is
because a number of the more controversial research
tool patents have not been granted in Australia and
there is little evidence of aggressive enforcement prac-
tices in relation to granted patents.10 The views
expressed by respondents on the value of particular
types of patents depend very much on the position in
the industry of the respondent. Respondents in down-
stream sectors object to upstream patents, but at the
same time vigorously defend downstream patents. For
respondents in the upstream sectors, however,
upstream patents are essential to their economic via-
bility.
While the importance of maintaining the free flow of
raw scientific data is widely recognised, this should not
be at the cost of unfair discrimination against certain
industry sectors. The cascade of patents that flows from
the upstream to the downstream sectors of the industry
inevitably increases the price of end products, but this
has to be balanced against the value of innovation at the
upstream end of the industry and the importance of
maintaining its economic viability.
Transfer of technology
The results of this study show that there is an extensive
network of collaborations within the Australian indus-
try, particularly between research institutions and
upstream or intermediate level companies. Overseas
collaborations are particularly important. The mecha-
nisms used to transfer technology within these collabor-
ative arrangements are many and varied. While
assignment of patents from research institutions to
companies was common in the past, there is now more
reluctance to relinquish control over the future develop-
ment of technology created in the research institution
setting.
Some participants in the Australian medical biotech-
nology industry are capable of bringing their own prod-
ucts to market, particularly in the device sector.
However, for the most part, particularly in the drug
discovery sector, participants need to be able to transfer
their technology downstream. Indeed, in most cases
there are a number of intermediate steps from the
research sector to the market. Most Australian biotech-
nology companies fall into the upstream and intermedi-
ate sectors. As such, the challenge for the Australian
industry is to make their technology attractive to down-
stream partners. In many cases this will require transfer
of technology overseas. Adequate patent protection is
just one of the challenges for the industry. At present
there appears to be a ‘‘buyers’ market’’ in the Australian
biotechnology industry. It is very difficult to find suita-
ble downstream partners and negotiate a good deal, but
not impossible.
The issues facing the Australian industry to some
extent mirror the industry elsewhere. While the rates of
technology transfer in Australia are encouraging, the
process is not without its impediments. Ways need to be
found for making the process as streamlined as possi-
ble.
10 Results of searches for these research tool patents in Aus-
tralia are provided in the Nicol and Nielsen Report, n.5 above, at
pp.41–48.
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Issues for research institutions
Australian research institutions continue to be rich
sources of high-quality research results, many of which
have great potential for commercialisation. Participants
in the research sector accept that patenting is an essen-
tial component of the commercialisation process. Like
company participants, they see that obtaining patents is
necessary to ensure the flow of investment for research
and development. Scientists in research institutions in
Australia are becoming more knowledgeable about
intellectual property issues, and research institutions
are putting better strategies in place than was the case in
the last decade. Some of the important features of good
intellectual property strategies include:
u open dialogue between scientists, technology
transfer officers and patent attorneys;
u clean ownership through assignment to the insti-
tution (although Melbourne University has the
strategy of vesting ownership in the inventor);
u rapid review of publications to ensure that they do
not compromise future intellectual property; and
u clear profit-sharing arrangements.
Two issues raised by respondents that are of some con-
cern are the quality of patent applications and the valu-
ing of technology. Some respondents reported that
there is a tendency both to over-file and to over-value.
However, as research institutions become more familiar
with intellectual property management strategies it is
likely that they will find ways to work around these
problems. Many of these issues could be (and are being)
addressed through the implementation of better man-
agement procedures. In the area of law reform, there is
one particular matter that needs to be addressed. The
scope of the current research exemption (if it exists at
all) is far from clear. Although clarification of this
exemption is highly desirable, it may be that this would
have little practical effect because much biomedical
research has commercial implications at some stage.11
Restrictions on access
This study revealed evidence of liberal licensing prac-
tices associated with some essential or foundational
inventions within the Australian industry. Respondents
reported having little difficulty gaining access to broadly
applicable research tools and technologies. It was not
quite so clear that this was the case with technology
useful to produce two competing products. There were
a number of scenarios where access to technology of
this type appeared to have been restricted in some way,
and if so it is possible that innovation may be impeded.
Although it cannot be concluded with any certainty how
frequently this had occurred, there were certainly
instances of it. Many respondents did, however, report
being able to either access technology they needed, or
redirect their research efforts. But access was often
gained at a cost. The imposition of terms claiming
reach-through rights is commonplace, and numerous
other terms that slow the pace of negotiations are fre-
quently sought. Even when a negotiated outcome is
reached, the pace of innovation may be slowed. The
cost to the industry is significant, but the social cost
may be greater.
It would be premature to conclude that exclusionary
practices in relation to patented technology within the
Australian biotechnology industry are having a minimal
effect on innovation. There was substantial evidence in
this study of exclusionary practices, but this to some
extent is to be expected in any patent system. The ques-
tion that needs to be addressed is whether exclusionary
practices are having a negative impact on innovation
and the development of the industry.
Anticommons issues
There is no doubt that the increasing complexity of the
patent landscape is creating difficulties for the Austra-
lian medical biotechnology industry. In particular,
searching obligations are onerous and expensive.
Nevertheless, as with other studies, the results of this
study suggest that for any particular research project the
number of problematic patents is quite small, generally
less than five. However, it is concluded that in part the
reason for this is that if there is a higher level of encum-
brance research will be redirected. It is difficult to state
with any level of precision the number of research pro-
jects that are abandoned for the reason that there are
too many problematic patents in the area, but it is
acknowledged that this problem does exist.
Because most participants in the Australian industry
need to license out their patents, they are very conscious
about the need to keep their technology as attractive as
possible to downstream partners. One of the critical
factors is the need to avoid over-encumbrance. Partici-
pants in the Australian industry are conscious of royalty
stacking and endeavour to keep this to a minimum in
their licensing-in activities.
Respondents in this study did not report significant
problems associated with the enforcement of multiple
research tool patents. In part this is because a number
of the most aggressively enforced research tool patents
do not exist in Australia, or, if they do exist, they do not
appear to be enforced.12 However, these or other
research tool patents may well be enforced in the future.
Hence it would be premature to say that the Australian
industry is free from the rigours of research tool patent
enforcement.
Impact on end users: the provision of diagnostic
services
Although biotechnology patents have the capacity to
impact on many types of health care products, this
study primarily focused on the issue of supply of diag-
nostic services. In contrast to a recent study in the
United States, there was little evidence of enforcement
11 Note that in addition to the Australian Law Reform Com-
mission inquiry (see ALRC Report, n.1 above), a second inde-
pendent inquiry is being conducted by the Australian Advisory
Council on Intellectual Property. The Council released its
Options Paper, Patents and Experimental Use, in December 2004.
Available at www.acip.gov.au/reviews.htm#expuse (last accessed
May 18, 2005). At the time of writing the final report has not yet
been released. 12 See n.10 above.
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of patents in this area in Australia, apart from one nota-
ble exception: some respondents commented that they
had received demands for licence fees by Hoffmann-La
Roche for in-house production of taq polymerase for
use in the polymerase chain reaction. In addition, since
the completion of this study it appears likely that diag-
nostic testing facilities may have received similar
demands from Genetic Technologies Ltd (‘‘GTG’’), a
Melbourne-based company, relating to its patents
claiming intron sequence analysis. Like the polymerase
chain reaction, this technology is a foundational
research tool for much modern biomedical research.
Dr. Mervyn Jacobson, the chief executive officer of
GTG, has intimated that these patents are now being
enforced against Australian diagnostic facilities.13
Respondents in this area have far greater concerns
abut the effect of patents on research than respondents
from either of the other two sectors. In addition, many
have concerns about the impact of patents on the provi-
sion of diagnostic tests to end users. Because the owners
of gene patents do have the capacity to exert significant
influence on the provision of these services, options for
law reform may need to be scrutinised more closely in
this area than in others.
Market solutions
When faced with the knowledge that they might be
infringing a patent, most respondents said that their
first option would be to attempt to negotiate a licence.14
The Australian industry relies heavily on licensing
arrangements: over half of the research institution and
company respondents in this study that owned patents
reported licensing-out activities. Similarly, around half
of all research institution and company respondents
also reported in-licensing. Notwithstanding this evi-
dence of significant licensing activity, there are also sig-
nificant challenges. Negotiating difficulties, restrictive
licence terms, refusals to license and stacking royalties
can all create impediments to a well-functioning mar-
ket. There are doubtless cases where unhindered
research and development is impossible.
One of the other main ways to avoid patent infringe-
ment is to invent around patented technology. This is
easier to do in some areas than in others; it is generally
made more difficult when broad patents are granted.
Moreover, significant costs are involved in finding
appropriate ways to invent around. One other option
when a particular area of research is discovered to be
infringing a patent is to ignore it. Many respondents in
research institutions rely on the argument that their
research is exempt. Indeed, although the law in this area
is unclear in Australia, there is some evidence to suggest
that a practice-based research exemption exists. Com-
panies are unwilling to enforce their patents against
researchers in research institutions both because it
would create a negative image against the company and
also because research institutions lack the financial
resources to make legal challenge worthwhile. However,
this attitude may not continue into the future.
There is also some evidence of patents being ignored
in the company sector. Similarly, in the diagnostics
area, it appears that most patents are ignored. The risk
from the individual perspective is that if caught the
individual could face a large damages award and/or an
injunction preventing them from continuing their
research. From the broader social perspective, such
actions could be seen to be undermining the social
value of the patent system. Patent holders encounter
serious difficulties in tracking infringers. In particular,
infringement of research tool patents is notoriously dif-
ficult to detect. Even when infringement has been
detected, enforcement is a high-cost procedure and
there is a risk that once infringement proceedings are
initiated a counter-claim could be made for revoca-
tion.
Some industry participants will look at the option of
challenging the validity of patents, either in pre-grant
opposition proceedings or post-grant revocation. How-
ever, the costs are significant and such challenges can-
not be embarked upon lightly. One of the difficulties
this presents in Australia is that because of the costs
there are few challenges and because of this there is little
in the way of precedent. This increases the risks asso-
ciated with litigation in this area. As a consequence,
many patents that may be invalid are never challenged,
emphasising the importance of granting good patents or
of better enabling challenges to questionable patents.
Research institution patent holders in particular are
unlikely to be able to take the step of challenging com-
petitors’ patents because of lack of resources and risk-
averse strategies.
Reform options
Although working solutions are being found by industry
participants to many of the problems associated with
biotechnology patents and technology transfer, some
consideration of options for law reform is warranted.
Legal solutions can be broadly categorised into solu-
tions that regulate the grant of patents and solutions
that regulate in some way the manner in which patents
are used.
Regulating the grant of patents
The results of this study suggest that wholesale reform
of the patent-granting requirements is not desirable at
this time. However, this does not preclude a considera-
tion of a refinement of patent standards and ways in
which the grant of patents might be constrained.
Indeed, many commentators have called for such a con-
sideration. For example, two members of a working
group on research tools commissioned by the US
National Institutes of Health expressed concern about
13 See the Australian Broadcasting Corporation Four Corners
programme, ‘‘Patently a Problem’’, broadcast on August 11,
2003, transcript available at www.abc.net.au/4corners/content/
2003/transcripts/3922059.htm (last accessed May 18, 2005).
14 Low levels of cross-licensing were also reported in order to
overcome blocking patent situations. Blocking patents occur
where one patent holder holds a broad patent over an invention
(the dominant patent) and another patent holder holds a nar-
rower patent over an improvement to that invention, or a new
invention (the subservient patent). See R. Merges and R. Nel-
son, ‘‘On the Complex Economics of Patent Scope’’ (1995) 90
Columbia Law Review 839.
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the ways in which patent standards were applied in bio-
technology.15 Fine-tuning the patent system in biotech-
nology was considered by them to be a necessary
exercise.
As noted above, the results of this study indicate that
there is a need to improve examination practices in
Australia to ensure that good-quality patents are issued.
This is particularly important because pre- and post-
grant challenges to validity do not occur routinely
enough to strike out invalid patents or to provide guid-
ance as to examination of other patents. However, a
gene sequence exclusion or a ordre public/morality exclu-
sion is unlikely to add a great deal and may in fact create
uncertainty. The following options warrant further
consideration:
u the addition of an industrial applicability/utility
requirement at the examination stage; and
u the crafting of more biotechnology-specific guide-
lines for assessing the description criteria.
Recommendations resulting from the inquiry into gene
patenting conducted by the Australian Law Reform
Commission largely support these options for
reform.16
Regulating the use of patents
There are various options for regulating the use of pat-
ents, each of which warrants closer scrutiny.17 However,
any proposals for reform must be carefully evaluated
before implementation because any option that is aimed
at promoting access will have some impact on technol-
ogy providers.18 There is certainly room for improve-
ment in streamlining technology transfer practices.
There is some desirability for finding ways of reducing
the onerous demands of patent searching and tracking
infringement. Moreover, it may be desirable to have
standard term licensing contracts in some areas, with
standard licence fees. In particular, it may be appro-
priate to consider some of these measures in the areas of
non-profit research, diagnostics and research tool
licensing. However, such measures should not be
adopted in any wholesale way across the industry. In
most instances freedom of contract should prevail.
While there may be some desirability in relaxing the
compulsory licensing procedures, this should not be at
the cost of devaluing the patent grant. It may be more
fruitful to look at co-regulatory mechanisms for regulat-
ing the use of patents. In this regard, some of the mech-
anisms employed under the Australian copyright system
may provide guidance.
Competition law may also provide an appropriate
vehicle for addressing some access issues, and exists as
a remedy in the event of anti-competitive practices. It is,
however, rarely utilised in relation to restricted access to
intellectual property, and this suggests that there could
be some difficulties promoting its use to address exclu-
sionary licensing practices. Given the confidential
nature of many transactions involving intellectual prop-
erty, carving out a role for competition law may be
difficult. Any extension of the role of competition law
should be evaluated very carefully.
Each issue raises complex questions and implications
for the industry. As such, caution is required in the
implementation of law reform to ensure that the
momentum of the industry is sustained.
15 National Institutes of Health, Report of the National Institutes
of Health Working Group on Research Tools (1998), available at
www.nih.gov./news/researchtools/index.htm (last accessed May 18,
2005) at fn.5 of that Report.
16 See ALRC Report, n.1 above, particularly Recommenda-
tions 6-1 to 6-4, &-1 and 8-2.
17 The ALRC Report, n.1 above, canvasses many of these
options. See particularly Chs 23, 24, 26 and 27.
18 The ALRC Report, n.1 above, emphasises the importance
of a ‘‘nuanced approach to reform’’ at p.14.
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